TREATMENT ACCESS
- Bush plans $15 billion budget to treat two million people and prevent seven million infections in 14 countries – but meets criticism from activists
- World Health Organisation must continue its work on access to medicines in developing countries
- Dr Jong-Wook Lee nominated to be WHO director-general
- AAI Pharma access programme providing treatment for 36,000 people in Africa
- Pharmacia to launch pilot programme for expanding access to medicines in the poorest countries
- Heineken to offer antiretroviral drugs to African workforce
- Five pharmaceutical companies to halve antiretroviral drug prices for central America
- Patent law overrides would not expand access to drugs for low-income nations, opinion piece says
ANTIRETROVIRALS
- Efficacy and safety of a quadruple combination Combivir + abacavir + efavirenz regimen in antiretroviral treatment-naive HIV-1-infected adults: La Francilienne
- Subtle decreases in stavudine phenotypic susceptibility predict poor virologic response to stavudine monotherapy in zidovudine-experienced patients
RESISTANCE
- Medical care providers have very limited knowledge of resistance-associated drug mutations
- Inhibitory quotient useful as indicator of effective protease inhibitor therapy
METABOLIC TOXICITIES AND SIDE EFFECTS
- 30-year study links vitamin A to risk of fracture in humans
- Bone turnover elevated in HIV-positive patients and linked to duration of HAART
- Efavirenz effects worse than reported, study says
- Protease inhibitors and cardiovascular outcomes in patients with HIV-1
- HIV protease inhibitors promote atherosclerosis independent of dyslipidemia
- HAART-associated hyperlipidemia linked to low risk for cardiovascular disease (CVD)
- Patient on human growth hormone develops tumours with growth hormone receptors
- Review of trials shows testosterone increases lean body mass, and is most effective when given intramuscularly
IMMUNOLOGY
OPPORTUNISTIC INFECTIONS
- Rituximab and chemotherapy is highly effective in patients with CD20-positive non-Hodgkin’s lymphoma and HIV
- Lung cancer in HIV-positive HAART users
- Functional MRI can find brain abnormalities in asymptomatic patients
HEPATITIS AND COINFECTION
- Hepatitis C virus viraemia in HIV-infected individuals with negative HCV antibody tests
- Roche’s Copegus (ribaviran) available in UK for use in the treatment of Hepatitis C
- PEG-Intron plus ribavirin in non-responders and relapsers
- Dangers of HIV/hepatitis B coinfection
OTHER NEWS
- SILCAAT IL-2 study saved as investigators take over responsibility and Chiron agrees to continue funding
- Drug industry contributions influence clinical research
- Accuracy of pharmaceutical advertisement in medical journals
- Lack of new drugs is reaching crisis point, says review
- Medicines Control Agency must be more open
ON THE WEB including
- Conference abstracts and reports from 4th International Workshop on Lipodystrophy
- Drug Development for Antiretroviral Therapies , 40th ISDA, 53rd AASLD
- 40th Annual Meeting of the Infectious Diseases Society of America
- 53rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
- Medscape article including: Is there a pipeline? and AIDS articles in full
- Contents of newsletters now online: The Hopkins HIV Report, PRN Notebook, IAPAC, TAGline, IAVI Report
- Spanish guidelines on management of HIV coinfection with Hepatitis A, B and C
- Think tank explores liver transplants in HIV/AIDS
- In HIV vaccine efforts, new strategies and patience are needed in equal measure
- Treatment issues for women
- Depression and HIV
- Resistance algorithms updated
h-tb HIV Treatment Bulletin HTB
is a monthly journal published in print and electronic format by
HIV i-Base. As with all i-Base publications, subscriptions are
free and can be ordered directly from the i-Base website: by sending
an email to: |
Editor:
Simon Collins |
HTB is a non-for-profit community publication that aims to provide an review of the most important medical advances related to clinical management of HIV and its related conditions as well as access to treatments.
Many articles are reproduced from other established community sources and copyright for these articles remains with the original authors and sources, as indicated at the end of each article.
We thank those organisations for recognising the importance of providing widely distributed free access to information both to people living with HIV and to healthcare professionals involved in their care. We also thank them for permission to distribute their excellent work and we encourage HTB readers to visit the source websites for further access to their coverage of HIV treatment.
Articles written and credited to i-Base writers, as with all i-Base originated material, remains copyright-free and reproduction is encouraged. These articles only may be reproduced by community and not-for-profit organisations without individual written permission although a credit and link to the original author, the HTB issue and the i-Base website is always appreciated.